MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1186/s13054-021-03753-9

Медицинская библиотека · Critical care (London, England) · 2021

Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study.

Hatzl Stefan, Reisinger Alexander C, Posch Florian, Prattes Juergen, Stradner Martin, Pilz Stefan, Eller Philipp, Schoerghuber Michael, Toller Wolfgang, Gorkiewicz Gregor, Metnitz Philipp, Rief Martin, Prüller Florian, Rosenkranz Alexander R, Valentin Thomas, Krause Robert, Hoenigl Martin, Schilcher Gernot

СтатьяНаблюдательное исследованиеПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

BACKGROUND

Coronavirus disease 19 (COVID-19)-associated pulmonary aspergillosis (CAPA) emerged as important fungal complications in patients with COVID-19-associated severe acute respiratory failure (ARF). Whether mould active antifungal prophylaxis (MAFP) can prevent CAPA remains elusive so far.

METHODS

In this observational study, we included all consecutive patients admitted to intensive care units with COVID-19-associated ARF between September 1, 2020, and May 1, 2021. We compared patients with versus without antifungal prophylaxis with respect to CAPA incidence (primary outcome) and mortality (secondary outcome). Propensity score adjustment was performed to account for any imbalances in baseline characteristics. CAPA cases were classified according to European Confederation of Medical Mycology (ECMM)/International Society of Human and Animal Mycoses (ISHAM) consensus criteria.

RESULTS

We included 132 patients, of whom 75 (57%) received antifungal prophylaxis (98% posaconazole). Ten CAPA cases were diagnosed, after a median of 6 days following ICU admission. Of those, 9 CAPA cases were recorded in the non-prophylaxis group and one in the prophylaxis group, respectively. However, no difference in 30-day ICU mortality could be observed. Thirty-day CAPA incidence estimates were 1.4% (95% CI 0.2-9.7) in the MAFP group and 17.5% (95% CI 9.6-31.4) in the group without MAFP (p = 0.002). The respective subdistributional hazard ratio (sHR) for CAPA incidence comparing the MAFP versus no MAFP group was of 0.08 (95% CI 0.01-0.63; p = 0.017).

CONCLUSION

In ICU patients with COVID-19 ARF, antifungal prophylaxis was associated with significantly reduced CAPA incidence, but this did not translate into improved survival. Randomized controlled trials are warranted to evaluate the efficacy and safety of MAFP with respect to CAPA incidence and clinical outcomes.

Для цитирования: Hatzl Stefan, Reisinger Alexander C, Posch Florian, Prattes Juergen, Stradner Martin, Pilz Stefan, Eller Philipp, Schoerghuber Michael, Toller Wolfgang, Gorkiewicz Gregor, Metnitz Philipp, Rief Martin, Prüller Florian, Rosenkranz Alexander R, Valentin Thomas, Krause Robert, Hoenigl Martin, Schilcher Gernot. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study.. Critical care (London, England). 2021. DOI: 10.1186/s13054-021-03753-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.